Cytokinetics Inc vs Dow Inc — how do they compare? Cytokinetics Inc trades at $76.66 (market cap $10.78B), while Dow Inc trades at $31.2 (market cap $22.09B). The key difference: Dow Inc is far larger — about 2× Cytokinetics Inc's market cap, and Dow Inc pays a 4.58% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | DOW | |
|---|---|---|
Market Cap | $10.78B | $22.09B |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $41.87 |
52-Week Low | $34.31 | $20.65 |
Enterprise Value | $10.88B | $37.78B |
Dividend Yield | — | 4.58% |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →